drugset / Trial / NCT00089921
SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to determine the efficacy of oral SCIO-469 in patients with rheumatoid arthritis who are not receiving liver damaging (hepatotoxic) disease-modifying anti-rheumatic drugs (DMARDs).
Timeline
- Start
- 2004-07
- Primary completion
- —
- Completion
- 2005-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TALMAPIMOD | Small molecule | 30 mg | Oral |
| Subject | TALMAPIMOD | Small molecule | 60 mg | Oral |
| Subject | TALMAPIMOD | Small molecule | 100 mg | Oral |